Recently, Syntellix AG has been granted the national approvals for MAGNEZIX^® for the following countries: Australia, New Zealand, Saudi Arabia and Jordan. As a result, the company currently has international approvals in 48 countries for its biotransformable magnesium implants (MAGNEZIX ^® CS; MAGNEZIX^® Pin: 38 countries at the moment) and further expands its pioneering role and technology leadership.

Prof. Dr. Martin Kirschner (Member of the Board, CTO) sees this development as evidence of an impressive team performance: "We are, of course, in constant contact with the competent authorities to implement the approvals promptly. However, the fact that we were able to implement several complex approval processes in several countries simultaneously and in record time is due to the competence, the foresight and the joint commitment of our employees."

Thomas Mayer, CEO of Syntellix, adds, "These approvals and the markets represented by them are not only a crucial element of our internationalization strategy but also an important step towards our goal of providing as many people worldwide with magnesium implants, So that they too can profit from their unique advantages. This vision continues to drive us - and in 2017 we will continue to keep up the pace."